Improving Online Experiences, Workflows and Customized Content Delivery Just Got Easier With Limelight Networks’ New EdgeFunctions
8.9.2020 17:26:00 EEST | Business Wire | Press release
Limelight Networks, Inc. (Nasdaq: LLNW), a leading provider of content delivery network (CDN) and edge cloud services, has expanded its edge capabilities by launching EdgeFunctions, a new serverless compute service which allows developers to tap into the power of the company’s global network and gives them the flexibility to deploy and run their own code.
EdgeFunctions provides a customizable environment at the network edge for streamlining content workflows, performing time-sensitive decisions, and customizing user experiences. Providing this environment at the network edge offers Limelight’s low latency, on-demand scalability and high-performance network to developers. EdgeFunctions is ideal for streaming video and content delivery use cases such as personalized streaming, content protection, dynamic ad insertion, A/B testing, and image manipulation. Functions are globally available in Limelight’s highly distributed network and run closest to where content requests are received, ensuring Limelight’s lowest possible latency for code execution and optimal user experiences.
“We are thrilled to partner with Limelight to integrate our NexGuard Streaming forensic watermarking technology with EdgeFunctions and safeguard a premium OTT provider’s content from leaks and piracy,” said Jean-Philippe Plantevin, VP Anti-Piracy at NAGRA, a leading provider of content protection and multiscreen TV solutions. “Using EdgeFunctions, we were able to quickly deploy our customized solution into Limelight’s network edge locations and run them on demand, at scale, for both VOD and live OTT watermarking workflows.”
EdgeFunctions leverages Limelight’s global network to put flexibility and power directly into the hands of developers with support for several programming languages including Node.js, Python and Go. Its APIs enable these developers to manage, deploy and run their functions at the network edge and take advantage of Limelight’s direct peering connections with more than 1,000 ISPs and leading public cloud providers.
“Edge technology and solutions are rapidly expanding to meet a diverse set of customer needs. Limelight has an extensive global network with edge locations across the globe,” said Dave McCarthy, Research Director, Edge Strategies at IDC. “Giving developers more dynamic control over content combined with Limelight’s extensive global network optimizes the delivery of video at the edge.”
EdgeFunctions is Limelight’s latest innovation in the company’s edge compute solutions. These edge compute solutions now include serverless, virtual machine and bare metal solutions, providing edge compute capabilities how and where customers need them. In 2018 Limelight launched its first Edge Compute offering that allowed customers to access a highly connected environment that delivers low latency by combining globally distributed compute power with Limelight's high-performance network.
“We’ve evolved beyond high performing online video delivery with new innovative solutions to enhance online experiences and provide real value to our customers in ways that only we can. Now developers have the power to create and run bandwidth-intensive, latency-sensitive applications throughout our network edge,” said Bob Lento, CEO at Limelight. “Our extensive Edge Compute offering coupled with EdgeFunctions provides one of the most comprehensive content delivery and edge tool sets available today, and we have a robust development pipeline with much more to come. I’m thrilled to provide these services to the world’s leading companies.”
About Limelight
Limelight Networks, Inc. (NASDAQ: LLNW) is a global leader in delivering the highest quality online video experiences and edge-enabled workflows. Limelight has successfully helped launch and grow the largest video properties in the world and is on the forefront of enabling a new generation of applications that will disrupt markets and change our world.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200908005739/en/
Contact information
Press
Stephanie Epstein
SHIFT Communications
Limelight@shiftcomm.com
617-779-1800
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom